Table 4. Hazard ratios for recurrence-free survival and overall survival in HCC patients who underwent hepatic resection: Multivariable cox regression analysis.
| Variable | RFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | (95% CI) | P | HR | (95% CI) | P | |
| Age ≥ 70 years (vs. < 70 years) | 1.26 | (0.63–2.49) | 0.514 | 2.31 | (0.73–7.32) | 0.156 |
| Sex female (vs. male) | 1.89 | (0.81–4.43) | 0.143 | 0.59 | (0.12–2.95) | 0.517 |
| DM present (vs. absent) | 0.71 | (0.33–1.53) | 0.383 | 2.40 | (0.66–8.75) | 0.186 |
| HCVAb positive (vs. negative) | 2.43 | (1.19–4.97) | 0.015 | 0.67 | (0.19–2.35) | 0.530 |
| Platelet count ≥ 15.7×104/mm3 (vs. < 15.7×104/mm3) | 1.47 | (0.77–2.80) | 0.238 | 0.69 | (0.24–1.96) | 0.480 |
| Prothrombin activity ≥ 87% (vs. < 87%) | 2.78 | (1.31–5.88) | 0.008 | 1.46 | (0.39–5.46) | 0.571 |
| Serum albumin ≥ 4.0 g/dL (vs. < 4.0 g/dL) | 0.74 | (0.35–1.53) | 0.416 | 0.58 | (0.18–1.88) | 0.360 |
| ALT ≥ 40 (vs. < 40) | 1.44 | (0.74–2.82) | 0.285 | 0.71 | (0.21–2.46) | 0.592 |
| Serum total bilirubin ≥ 0.7 mg/dL (vs. < 0.7 mg/dL) | 1.50 | (0.66–3.42) | 0.338 | 1.49 | (0.32–6.84) | 0.610 |
| Alpha-fetoprotein ≥ 8.0 ng/mL (vs. < 8.0 ng/mL) | 0.67 | (0.34–1.32) | 0.248 | 1.88 | (0.48–7.32) | 0.361 |
| PIVKA-II ≥ 46 mAU/mL (vs. < 46 mAU/mL) | 3.10 | (1.36–7.09) | 0.007 | 3.37 | (0.73–15.64) | 0.120 |
| Tumor number ≥ 2 (vs. single) | 2.61 | (1.13–6.01) | 0.024 | 1.78 | (0.47–6.71) | 0.394 |
| Tumor size ≥ 30 mm (vs. < 30 mm) | 0.71 | (0.35–1.47) | 0.358 | 0.55 | (0.18–1.76) | 0.316 |
| vp and/or vv positive (vs. negative) | 0.84 | (0.33–2.15) | 0.723 | 0.53 | (0.12–2.31) | 0.395 |
| Tumor stage III or IVa (vs. I or II) | 1.55 | (0.60–3.99) | 0.366 | 0.56 | (0.12–2.60) | 0.461 |
| More than hemihepatectomy (vs. less than hemihepatectomy) | 0.87 | (0.36–2.10) | 0.761 | 0.33 | (0.05–2.27) | 0.260 |
| Operative blood loss ≥ 500 ml (vs. < 500 ml) | 1.20 | (0.61–2.38) | 0.601 | 1.62 | (0.51–5.20) | 0.413 |
| Total weight by DEXA (rate of change) ≥ 100% (vs. < 100%) | 0.76 | (0.32–1.79) | 0.530 | 0.25 | (0.05–1.15) | 0.074 |
| Non-fat content by DEXA (rate of change) ≥ 100% (vs. < 100%) | 1.42 | (0.74–2.75) | 0.291 | 2.65 | (0.93–7.58) | 0.068 |
| Peak VO2 (rate of change) ≥ 90% (vs. < 90%) | 2.47 | (1.03–5.94) | 0.043 | 1.36 | (0.31–6.02) | 0.687 |
| AT VO2 (rate of change) ≥ 90% (vs. < 90%) | 2.58 | (1.22–5.46) | 0.013 | 5.03 | (1.40–18.02) | 0.013 |
RFS, recurrence-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; HCVAb, hepatitis C virus antibody; ALT, alanine aminotransferase; PIVKA-II, protein induced by vitamin K absence-II; vp, portal vein invasion; vv, hepatic vein invasion; DEXA, dual-energy X-ray absorptiometry; AT, anaerobic threshold; VO2, oxygen consumption.